Stefan Bittner

List of Publications by Year
in descending order

146 papers	4,844 citations	87723 38 h-index	128067 60 g-index
154 all docs	154 docs citations	154 times ranked	7113 citing authors

#	Article	IF	Citations
1	Regulatory T cells are strong promoters of acute ischemic stroke in mice by inducing dysfunction of the cerebral microvasculature. Blood, 2013, 121, 679-691.	0.6	300
2	Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond. International Journal of Molecular Sciences, 2015, 16, 16414-16439.	1.8	167
3	Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 678-686.	1.4	148
4	Endothelial TWIK-related potassium channel-1 (TREK1) regulates immune-cell trafficking into the CNS. Nature Medicine, 2013, 19, 1161-1165.	15.2	136
5	Myelin Oligodendrocyte Glycoprotein (MOG₃₅₋₅₅) Induced Experimental Autoimmune Encephalomyelitis (EAE) in C57BL/6 Mice. Journal of Visualized Experiments, 2014, , .	0.2	110
6	Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells. Nature Communications, 2016, 7, 11626.	5.8	105
7	The potential of serum neurofilament as biomarker for multiple sclerosis. Brain, 2021, 144, 2954-2963.	3.7	98
8	Stromal Interaction Molecules 1 and 2 Are Key Regulators of Autoreactive T Cell Activation in Murine Autoimmune Central Nervous System Inflammation. Journal of Immunology, 2010, 184, 1536-1542.	0.4	96
9	NfL (Neurofilament Light Chain) Levels as a Predictive Marker for Long-Term Outcome After Ischemic Stroke. Stroke, 2019, 50, 3077-3084.	1.0	92
10	TWIK-related Acid-sensitive K+ Channel 1 (TASK1) and TASK3 Critically Influence T Lymphocyte Effector Functions. Journal of Biological Chemistry, 2008, 283, 14559-14570.	1.6	89
11	TASK1 modulates inflammation and neurodegeneration in autoimmune inflammation of the central nervous system. Brain, 2009, 132, 2501-2516.	3.7	88
12	Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110396.	1.5	86
13	Transient Receptor Potential Melastatin Subfamily Member 2 Cation Channel Regulates Detrimental Immune Cell Invasion in Ischemic Stroke. Stroke, 2014, 45, 3395-3402.	1.0	85
14	Cytotoxic CD8⁺T Cellâ€“Neuron Interactions: Perforin-Dependent Electrical Silencing Precedes But Is Not Causally Linked to Neuronal Cell Death. Journal of Neuroscience, 2009, 29, 15397-15409.	1.7	78
15	Blocking of Î±4 Integrin Does Not Protect From Acute Ischemic Stroke in Mice. Stroke, 2014, 45, 1799-1806.	1.0	78
16	Blockade of the kinin receptor B1 protects from autoimmune CNS disease by reducing leukocyte trafficking. Journal of Autoimmunity, 2011, 36, 106-114.	3.0	77
17	A Î²-Lactam Antibiotic Dampens Excitotoxic Inflammatory CNS Damage in a Mouse Model of Multiple Sclerosis. PLoS ONE, 2008, 3, e3149.	1.1	76
18	Smad7 in T cells drives T helper 1 responses in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain, 2010, 133, 1067-1081.	3.7	73

#	Article	IF	Citations
19	Isolation of Primary Murine Brain Microvascular Endothelial Cells. Journal of Visualized Experiments, 2014, , e52204.	0.2	72
20	IL-17+ CD8+ T cell suppression by dimethyl fumarate associates with clinical response in multiple sclerosis. Nature Communications, 2019, 10, 5722.	5.8	68
21	From the Background to the Spotlight: TASK Channels in Pathological Conditions. Brain Pathology, 2010, 20, 999-1009.	2.1	67
22	Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. EBioMedicine, 2020, 56, 102807.	2.7	67
23	Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 681-686.	0.9	66
24	Developmental endothelial locus-1 is a homeostatic factor in the central nervous system limiting neuroinflammation and demyelination. Molecular Psychiatry, 2015, 20, 880-888.	4.1	65
25	Monitoring B-cell repopulation after depletion therapy in neurologic patients. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e463.	3.1	65
26	Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	65
27	Maladaptive cortical hyperactivity upon recovery from experimental autoimmune encephalomyelitis. Nature Neuroscience, 2018, 21, 1392-1403.	7.1	64
28	Targeting B cells in relapsingâ€“remitting multiple sclerosis: from pathophysiology to optimal clinical management. Therapeutic Advances in Neurological Disorders, 2017, 10, 51-66.	1.5	62
29	Upregulation of K_{2P}5.1 potassium channels in multiple sclerosis. Annals of Neurology, 2010, 68, 58-69.	2.8	60
30	Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS. Multiple Sclerosis Journal, 2018, 24, 632-641.	1.4	57
31	A Novel Cervical Spinal Cord Window Preparation Allows for Two-Photon Imaging of T-Cell Interactions with the Cervical Spinal Cord Microvasculature during Experimental Autoimmune Encephalomyelitis. Frontiers in Immunology, 2017, 8, 406.	2.2	56
32	IL-17 Silencing Does Not Protect Nonobese Diabetic Mice from Autoimmune Diabetes. Journal of Immunology, 2012, 188, 216-221.	0.4	54
33	The neuroprotective impact of the leak potassium channel TASK1 on stroke development in mice. Neurobiology of Disease, 2009, 33, 1-11.	2.1	51
34	Human CD4 ⁺ HLAâ€G ⁺ regulatory T cells are potent suppressors of graftâ€versusâ€host disease <i>in vivo</i>. FASEB Journal, 2014, 28, 3435-3445.	0.2	51
35	Fast direct neuronal signaling via the IL-4 receptor as therapeutic target in neuroinflammation. Science Translational Medicine, 2018, 10, .	5.8	49
36	Protein kinase CÎ² as a therapeutic target stabilizing bloodâ€“brain barrier disruption in experimental autoimmune encephalomyelitis. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 14735-14740.	3.3	43

#	Article	IF	Citations
37	Evidence for early, non-lesional cerebellar damage in patients with multiple sclerosis: DTI measures correlate with disability, atrophy, and disease duration. Multiple Sclerosis Journal, 2016, 22, 73-84.	1.4	43
38	TREK-King the Bloodâ€“Brain-Barrier. Journal of NeuroImmune Pharmacology, 2014, 9, 293-301.	2.1	41
39	GFAPÎ± IgG-associated encephalitis upon daclizumab treatment of MS. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e481.	3.1	41
40	Volume regulation of murine T lymphocytes relies on voltage-dependent and two-pore domain potassium channels. Biochimica Et Biophysica Acta - Biomembranes, 2011, 1808, 2036-2044.	1.4	39
41	Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	38
42	The TASK1 channel inhibitor A293 shows efficacy in a mouse model of multiple sclerosis. Experimental Neurology, 2012, 238, 149-155.	2.0	37
43	The two-pore domain potassium channel TASK3 functionally impacts glioma cell death. Journal of Neuro-Oncology, 2008, 87, 263-270.	1.4	34
44	Blood-brain barrier modeling: challenges and perspectives. Neural Regeneration Research, 2015, 10, 889.	1.6	34
45	Î²1-Integrinâ€“ and KV1.3 channelâ€“dependent signaling stimulates glutamate release from Th17 cells. Journal of Clinical Investigation, 2020, 130, 715-732.	3.9	32
46	Functional characteristics of Th1, Th17, and ex-Th17 cells in EAE revealed by intravital two-photon microscopy. Journal of Neuroinflammation, 2020, 17, 357.	3.1	30
47	Pro-inflammatory T helper 17 directly harms oligodendrocytes in neuroinflammation. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	30
48	Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications. Neurotherapeutics, 2016, 13, 4-19.	2.1	29
49	CD4+NKG2D+ T Cells Exhibit Enhanced Migratory and Encephalitogenic Properties in Neuroinflammation. PLoS ONE, 2013, 8, e81455.	1.1	28
50	Phospholipase D1 mediates lymphocyte adhesion and migration in experimental autoimmune encephalomyelitis. European Journal of Immunology, 2014, 44, 2295-2305.	1.6	28
51	The Role of ERK Signaling in Experimental Autoimmune Encephalomyelitis. International Journal of Molecular Sciences, 2017, 18, 1990.	1.8	28
52	Exercise Diminishes Plasma Neurofilament Light Chain and Reroutes the Kynurenine Pathway in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	28
53	Collateral neuronal apoptosis in CNS gray matter during an oligodendrocyteâ€directed CD8⁺ T cell attack. Glia, 2010, 58, 469-480.	2.5	27
54	Ion channels in autoimmune neurodegeneration. FEBS Letters, 2011, 585, 3836-3842.	1.3	27

#	Article	IF	Citations
55	Natalizumab restores evoked potential abnormalities in patients with relapsingâ€"remitting multiple sclerosis. Multiple Sclerosis Journal, 2011, 17, 198-203.	1.4	27
56	Ocrelizumab initiation in patients with MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	26
57	Expression of K2P5.1 potassium channels on CD4+T lymphocytes correlates with disease activity in rheumatoid arthritis patients. Arthritis Research and Therapy, 2011, 13, R21.	1.6	25
58	Targeting ion channels for the treatment of autoimmune neuroinflammation. Therapeutic Advances in Neurological Disorders, 2013, 6, 322-336.	1.5	25
59	The Inflammatory Role of Platelets: Translational Insights from Experimental Studies of Autoimmune Disorders. International Journal of Molecular Sciences, 2016, 17, 1723.	1.8	25
60	Increase of Substance P Concentration in Saliva after Pharyngeal Electrical Stimulation in Severely Dysphagic Stroke Patients â€" an Indicator of Decannulation Success?. NeuroSignals, 2017, 25, 74-87.	0.5	25
61	The quality of cortical network function recovery depends on localization and degree of axonal demyelination. Brain, Behavior, and Immunity, 2017, 59, 103-117.	2.0	25
62	Therapeutic Approaches to Multiple Sclerosis. BioDrugs, 2010, 24, 317-330.	2.2	24
63	MOG encephalomyelitis: distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation. Journal of Neurology, 2020, 267, 1632-1642.	1.8	24
64	NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study. EBioMedicine, 2021, 72, 103590.	2.7	24
65	Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	24
66	Identification of two-pore domain potassium channels as potent modulators of osmotic volume regulation in human T lymphocytes. Biochimica Et Biophysica Acta - Biomembranes, 2013, 1828, 699-707.	1.4	23
67	Physiological Dynamics in Demyelinating Diseases: Unraveling Complex Relationships through Computer Modeling. International Journal of Molecular Sciences, 2015, 16, 21215-21236.	1.8	23
68	The CNS under pathophysiologic attackâ€"examining the role of K2P channels. Pflugers Archiv European Journal of Physiology, 2015, 467, 959-972.	1.3	23
69	Increased frequency of proinflammatory CD4 T cells and pathological levels of serum neurofilament light chain in adult drugâ€resistant epilepsy. Epilepsia, 2021, 62, 176-189.	2.6	23
70	Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity. Brain, 2022, 145, 1711-1725.	3.7	23
71	Therapeutic Approaches to Multiple Sclerosis. BioDrugs, 2010, 24, 249-274.	2.2	22
72	4-Aminopyridine ameliorates mobility but not disease course in an animal model of multiple sclerosis. Experimental Neurology, 2013, 248, 62-71.	2.0	22

#	Article	IF	Citations
73	A splice variant of the two-pore domain potassium channel TREK-1 with only one pore domain reduces the surface expression of full-length TREK-1 channels. Pflugers Archiv European Journal of Physiology, 2014, 466, 1559-1570.	1.3	22
74	Recombinant tandem of pore-domains in a Weakly Inward rectifying K+ channel 2 (TWIK2) forms active lysosomal channels. Scientific Reports, 2017, 7, 649.	1.6	22
75	Targeting Voltage-Dependent Calcium Channels with Pregabalin Exerts a Direct Neuroprotective Effect in an Animal Model of Multiple Sclerosis. NeuroSignals, 2018, 26, 77-93.	0.5	22
76	General control non-derepressible 2 (GCN2) in T cells controls disease progression of autoimmune neuroinflammation. Journal of Neuroimmunology, 2016, 297, 117-126.	1.1	21
77	The potassium channels TASK2 and TREK1 regulate functional differentiation of murine skeletal muscle cells. American Journal of Physiology - Cell Physiology, 2016, 311, C583-C595.	2.1	20
78	Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110355.	1.5	20
79	Two pore domain potassium channels in cerebral ischemia: a focus on K2P9.1 (TASK3, KCNK9). Experimental & Translational Stroke Medicine, 2010, 2, 14.	3.2	19
80	CD4+ CD25+ FoxP3+ regulatory T cells suppress cytotoxicity of CD8+ effector T cells: implications for their capacity to limit inflammatory central nervous system damage at the parenchymal level. Journal of Neuroinflammation, 2012, 9, 41.	3.1	19
81	Excitotoxic neuronal cell death during an oligodendrocyte-directed CD8+ T cell attack in the CNS gray matter. Journal of Neuroinflammation, 2013, 10, 121.	3.1	19
82	Association of intrathecal pleocytosis and IgG synthesis with axonal damage in early MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e679.	3.1	19
83	CNS-localized myeloid cells capture living invading T cells during neuroinflammation. Journal of Experimental Medicine, 2020, 217, .	4.2	18
84	Impact of Dietary Intervention on Serum Neurofilament Light Chain in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	18
85	Down-regulation of neuronal L1 cell adhesion molecule expression alleviates inflammatory neuronal injury. Acta Neuropathologica, 2016, 132, 703-720.	3.9	17
86	14â€3â€3 Proteins regulate K_{2P}5.1 surface expression on T lymphocytes. Traffic, 2017, 18, 29-43.	1.3	17
87	Continuous reorganization of cortical information flow in multiple sclerosis: A longitudinal fMRI effective connectivity study. Scientific Reports, 2020, 10, 806.	1.6	17
88	The NKG2D - IL-15 signaling pathway contributes to T-cell mediated pathology in inflammatory myopathies. Oncotarget, 2015, 6, 43230-43243.	0.8	17
89	Subcortical Volumes as Early Predictors of Fatigue in Multiple Sclerosis. Annals of Neurology, 2022, 91, 192-202.	2.8	17
90	Inhibition of the enzyme autotaxin reduces cortical excitability and ameliorates the outcome in stroke. Science Translational Medicine, 2022, 14, eabk0135.	5.8	17

#	Article	IF	Citations
91	Role of the epigenetic factor Sirt7 in neuroinflammation and neurogenesis. Neuroscience Research, 2018, 131, 1-9.	1.0	16
92	Cross-reactivity of a pathogenic autoantibody to a tumor antigen in GABA _A receptor encephalitis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	16
93	Improved prediction of early cognitive impairment in multiple sclerosis combining blood and imaging biomarkers. Brain Communications, 2022, 4, .	1.5	16
94	Intrathecal B-cell accumulation and axonal damage distinguish MRI-based benign from aggressive onset in MS. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e595.	3.1	15
95	Increased cerebrospinal fluid albumin and immunoglobulin A fractions forecast cortical atrophy and longitudinal functional deterioration in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 338-343.	1.4	15
96	Long-term efficacy of alemtuzumab in polymyositis. Rheumatology, 2015, 54, 560-562.	0.9	14
97	Dimethyl fumarate treatment restrains the antioxidative capacity of T cells to control autoimmunity. Brain, 2021, 144, 3126-3141.	3.7	14
98	K2P18.1 translates T cell receptor signals into thymic regulatory T cell development. Cell Research, 2022, 32, 72-88.	5.7	14
99	ALAIN01â€"Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential. BMC Neurology, 2016, 16, 34.	0.8	13
100	Altered neuronal expression of TASK1 and TASK3 potassium channels in rodent and human autoimmune CNS inflammation. Neuroscience Letters, 2008, 446, 133-138.	1.0	12
101	The twoâ€pore domain K₂P channel TASK2 drives human NKâ€cell proliferation and cytolytic function. European Journal of Immunology, 2015, 45, 2602-2614.	1.6	12
102	The two-pore domain potassium channel KCNK5 deteriorates outcome in ischemic neurodegeneration. Pflugers Archiv European Journal of Physiology, 2015, 467, 973-987.	1.3	12
103	Interleukin-4 receptor signaling modulates neuronal network activity. Journal of Experimental Medicine, 2022, 219, .	4.2	11
104	Glatiramer Acetate Attenuates Pro-Inflammatory T Cell Responses but Does Not Directly Protect Neurons from Inflammatory Cell Death. American Journal of Pathology, 2010, 177, 3051-3060.	1.9	10
105	Fingolimod (FTY720-P) Does Not Stabilize the Bloodâ€“Brain Barrier under Inflammatory Conditions in an in Vitro Model. International Journal of Molecular Sciences, 2015, 16, 29454-29466.	1.8	10
106	An N-terminal deletion variant of HCN1 in the epileptic WAG/Rij strain modulates HCN current densities. Frontiers in Molecular Neuroscience, 2015, 8, 63.	1.4	10
107	Detecting ongoing disease activity in mildly affected multiple sclerosis patients under first-line therapies. Multiple Sclerosis and Related Disorders, 2022, 63, 103927.	0.9	10
108	Ischemia-induced cell depolarization: does the hyperpolarization-activated cation channel HCN2 affect the outcome after stroke in mice?. Experimental & Translational Stroke Medicine, 2013, 5, 16.	3.2	9

#	Article	IF	Citations
109	Human T cells in silico: Modelling their electrophysiological behaviour in health and disease. Journal of Theoretical Biology, 2016, 404, 236-250.	0.8	9
110	Multiple sclerosis therapy consensus group (MSTCG): answers to the discussion questions. Neurological Research and Practice, 2021, 3, 44.	1.0	9
111	Effects of Glatiramer Acetate in a Spontaneous Model of Autoimmune Neuroinflammation. American Journal of Pathology, 2014, 184, 2056-2065.	1.9	8
112	Neuronal ICAM-5 Plays a Neuroprotective Role in Progressive Neurodegeneration. Frontiers in Neurology, 2019, 10, 205.	1.1	8
113	Association of serum neurofilament light chain levels and neuropsychiatric manifestations in systemic lupus erythematosus. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110514.	1.5	8
114	AAN unveils new guidelines for MS disease-modifying therapy. Nature Reviews Neurology, 2018, 14, 384-386.	4.9	7
115	Neurofilament light chain levels reflect outcome in a patient with glutamic acid decarboxylase 65 antibodyâ€“positive autoimmune encephalitis under immune checkpoint inhibitor therapy. European Journal of Neurology, 2021, 28, 1086-1089.	1.7	7
116	Absolute serum neurofilament light chain levels and its early kinetics predict brain injury after out-of-hospital cardiac arrest. Journal of Neurology, 2022, 269, 1530-1537.	1.8	7
117	Brain-derived neurotrophic factor and neurofilament light chain in cerebrospinal fluid are inversely correlated with cognition in Multiple Sclerosis at the time of diagnosis. Multiple Sclerosis and Related Disorders, 2022, 63, 103822.	0.9	7
118	T cellâ€“neuron interaction in inflammatory and progressive multiple sclerosis biology. Current Opinion in Neurobiology, 2022, 75, 102588.	2.0	7
119	Astrocytic potassium and calcium channels as integrators of the inflammatory and ischemic CNS microenvironment. Biological Chemistry, 2021, 402, 1519-1530.	1.2	6
120	Targeting CD52 does not affect murine neuron and microglia function. European Journal of Pharmacology, 2020, 871, 172923.	1.7	6
121	Selective Brain Network and Cellular Responses Upon Dimethyl Fumarate Immunomodulation in Multiple Sclerosis. Frontiers in Immunology, 2019, 10, 1779.	2.2	5
122	Supplementary medication in multiple sclerosis: Real-world experience and potential interference with neurofilament light chain measurement. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732093631.	0.5	5
123	Serum neurofilament levels reflect outer retinal layer changes in multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110034.	1.5	5
124	Active immunization with proteolipid protein (190-209) induces ascending paralysing experimental autoimmune encephalomyelitis in C3H/HeJ mice. Journal of Immunological Methods, 2011, 367, 27-32.	0.6	4
125	Evans syndrome associated with sterile inflammation of the central nervous system: a case report. Journal of Medical Case Reports, 2013, 7, 262.	0.4	4
126	Murine K2P5.1 Deficiency Has No Impact on Autoimmune Neuroinflammation due to Compensatory K2P3.1- and KV1.3-Dependent Mechanisms. International Journal of Molecular Sciences, 2015, 16, 16880-16896.	1.8	4

#	Article	IF	Citations
127	Disease reactivation after switching from natalizumab to daclizumab. Journal of Neurology, 2017, 264, 2491-2494.	1.8	4
128	The frequency of follicular T helper cells differs in acute and chronic neuroinflammation. Scientific Reports, 2020, 10, 20485.	1.6	4
129	Linking Microstructural Integrity and Motor Cortex Excitability in Multiple Sclerosis. Frontiers in Immunology, 2021, 12, 748357.	2.2	4
130	Mini-Review: Two Brothers in Crime â€“ The Interplay of TRESK and TREK in Human Diseases. Neuroscience Letters, 2022, 769, 136376.	1.0	4
131	A lymphocyte-glia connection sets the pace for smoldering inflammation. Cell, 2021, 184, 5696-5698.	13.5	4
132	Network alterations underlying anxiety symptoms in early multiple sclerosis. Journal of Neuroinflammation, 2022, 19, .	3.1	4
133	Progression in multiple sclerosis â€“ a long-term problem. Current Opinion in Neurology, 2022, 35, 293-298.	1.8	4
134	Comment on â€œFunctional consequences of Kv1.3 ion channel rearrangement into the immunological synapseâ€• Immunology Letters, 2009, 125, 156-157.	1.1	3
135	A role for TASK2 channels in the human immunological synapse. European Journal of Immunology, 2021, 51, 342-353.	1.6	3
136	Altered grey matter integrity and network vulnerability relate to epilepsy occurrence in patients with multiple sclerosis. European Journal of Neurology, 2022, 29, 2309-2320.	1.7	3
137	Immunotherapy of multiple sclerosis. Acta Neuropsychiatrica, 2009, 21, 27-34.	1.0	2
138	Intracellular fluoride influences TASK mediated currents in human T cells. Journal of Immunological Methods, 2020, 487, 112875.	0.6	2
139	Implications of extreme serum neurofilament light chain levels for the management of patients with relapsing multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110019.	1.5	2
140	An Ex vivo Model of an Oligodendrocyte-directed T-Cell Attack in Acute Brain Slices. Journal of Visualized Experiments, 2015, , .	0.2	1
141	TASK, TREK & Co.: a mutable potassium channel family for diverse tasks in the brain. E-Neuroforum, 2015, 6, 29-37.	0.2	1
142	Studying the bloodâ€“brain barrier will provide new insights into neurodegeneration â€“ Commentary. Multiple Sclerosis Journal, 2018, 24, 1026-1028.	1.4	1
143	Response by Uphaus et al to Letter Regarding Article, â€œNfL (Neurofilament Light Chain) Levels as a Predictive Marker for Long-Term Outcome After Ischemic Strokeâ€• Stroke, 2020, 51, e31.	1.0	1
144	TASK, TREK & Co.: Eine wandelbare Kalium-Kanalfamilie fÃ¼r diverse Aufgaben im Gehirn. E-Neuroforum, 2015, 21, .	0.2	0

#	Article	IF	Citations
145	TASK, TREK & Co.: a mutable potassium channel family for diverse tasks in the brain. E-Neuroforum, 2015, 21, .	0.2	0
146	Translational Value of CSF and Blood Markers of Autoimmunity and Neurodegeneration. Neuromethods, 2021, , 77-86.	0.2	0